Christopher T. Ritchlin mainly investigates Psoriatic arthritis, Arthritis, Psoriasis, Internal medicine and Rheumatology. Christopher T. Ritchlin combines subjects such as Physical therapy and Randomized controlled trial, Surgery with his study of Psoriatic arthritis. Christopher T. Ritchlin interconnects Psoriasis Area and Severity Index and Adalimumab in the investigation of issues within Surgery.
His research investigates the connection between Arthritis and topics such as Intensive care medicine that intersect with problems in Evidence-based medicine. His work carried out in the field of Psoriasis brings together such families of science as Pathology, Severity of illness, Rheumatoid arthritis and Ustekinumab. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Placebo, Endocrinology and Peripheral blood mononuclear cell.
His primary scientific interests are in Psoriatic arthritis, Internal medicine, Psoriasis, Arthritis and Rheumatology. His Psoriatic arthritis study frequently intersects with other fields, such as Adalimumab. His Internal medicine research integrates issues from Gastroenterology, Placebo and Surgery.
His Placebo study incorporates themes from Psoriasis Area and Severity Index, Randomized controlled trial and Ustekinumab. In his study, Infliximab is inextricably linked to Etanercept, which falls within the broad field of Psoriasis. His Arthritis study combines topics from a wide range of disciplines, such as Intensive care medicine, Rheumatoid arthritis and Pathology.
The scientist’s investigation covers issues in Psoriatic arthritis, Internal medicine, Psoriasis, Guselkumab and Placebo. Christopher T. Ritchlin has included themes like Medical physics and Etanercept in his Psoriatic arthritis study. In the subject of general Internal medicine, his work in Rheumatology, Arthritis and Adverse effect is often linked to In patient, thereby combining diverse domains of study.
His study explores the link between Arthritis and topics such as Rheumatoid arthritis that cross with problems in Tumor necrosis factor alpha and Lymphatic system. His biological study spans a wide range of topics, including Disease, MEDLINE, Family medicine and Intensive care medicine. His work deals with themes such as Psoriasis Area and Severity Index, Gastroenterology, Quality of life, Tildrakizumab and Post-hoc analysis, which intersect with Placebo.
Christopher T. Ritchlin spends much of his time researching Psoriatic arthritis, Internal medicine, Psoriasis, Rheumatology and Disease. He is interested in Enthesitis, which is a field of Psoriatic arthritis. Christopher T. Ritchlin combines topics linked to Placebo with his work on Internal medicine.
His Psoriasis study integrates concerns from other disciplines, such as Subclinical infection, Family medicine and Clinical trial. The study incorporates disciplines such as Combination therapy and Ustekinumab in addition to Rheumatology. His Arthritis study combines topics in areas such as Family aggregation, Natural history of disease, Rheumatoid arthritis and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
Philip P.J. Mease;Dafna D.D. Gladman;Christopher C.T. Ritchlin;Eric E.M. Ruderman.
Arthritis & Rheumatism (2005)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2) : a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B McInnes;Philip J Mease;Bruce Kirkham;Arthur Kavanaugh.
The Lancet (2015)
Mechanisms of TNF-α– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis
Christopher T. Ritchlin;Sally A. Haas-Smith;Ping Li;David G. Hicks.
Journal of Clinical Investigation (2003)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates;Arthur Kavanaugh;Philip J. Mease;Enrique R. Soriano.
Arthritis & Rheumatism (2016)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B McInnes;Arthur Kavanaugh;Alice B Gottlieb;Lluís Puig.
The Lancet (2013)
Treatment recommendations for psoriatic arthritis
C. T. Ritchlin;A. Kavanaugh;D. D. Gladman;P. J. Mease.
Annals of the Rheumatic Diseases (2009)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin;Proton Rahman;Arthur Kavanaugh;Iain B McInnes.
Annals of the Rheumatic Diseases (2014)
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
L Gossec;J S Smolen;C Gaujoux-Viala;Z Ash.
Annals of the Rheumatic Diseases (2012)
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
Josef S. Smolen;Jürgen Braun;Maxime Dougados;Paul Emery.
Annals of the Rheumatic Diseases (2014)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J Mease;Désirée van der Heijde;Christopher T Ritchlin;Masato Okada.
Annals of the Rheumatic Diseases (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: